Table 1.
Selection system | Year of proposal | Criteria | Survival/years of follow-up |
Milan criteria | 1996 | Single lesion ≤ 5 cm; up to three separate lesions, none larger than 3 cm; no evidence of gross vascular invasion; and no regional nodal or distant metastases | 85%/4[8] |
University of California, San Francisco criteria | 2007 | Single nodule up to 6.5 cm or up to three lesions, the largest of which is 4.5 cm or smaller and the sum of the diameters no larger than 8 cm | 80.9%/5[9] |
Up-to-seven criteria | 2009 | Sum of size (in cm) of larger tumor plus number of tumors ≤ 7 | 71.2%/5[12] |
Total tumor volume and alpha-fetoprotein criteria | 2009 | Total tumor volume ≤ 115 cm3 and alpha-fetoprotein ≤ 400 ng/mL, without macrovascular invasion or extrahepatic disease | 74.6%/4[11] |
Kyoto criteria | 2013 | ≤ 10 tumors; ≤ 5 cm; and des-gamma-carboxy prothrobine ≤ 400 mAU/mL | 65%/5[13] |
Extended Toronto criteria | 2016 | Any size or number of tumors, without systemic cancer-related symptoms, extrahepatic disease, vascular invasion, or a poorly differentiated largest lesion at percutaneous tumor biopsy. | 68%/5[10] |